AMARIN CORP PLC

Explore how Amarin Corporation PLC pioneers cardiovascular therapeutics, blending EU financial strategy with cutting‑edge biotech R&D to boost U.S. heart‑care outcomes.

Amarin’s FDA approval of apolipoprotein C-III therapy boosts treatment options for severe hypertriglyceridemia, positioning VASCEPA as the affordable first‑line choice.

Amarin Corporation PLC’s rising stock and €291 billion market cap show its leadership in cardiovascular biotech, driving innovative therapies and investor confidence.

Amarin Corporation PLC

Amarin’s AGM highlights board re‑elections, cautious investor stance on equity plans, and a setback for electronic proxy delivery—showing a conservative shift in biotech governance and strategy.

Amarin’s latest equity‑compensation move: new RSU grants, ownership shifts and a robust internal governance strategy aimed at rewarding key talent and driving biotech innovation for cardiovascular therapeutics.

Amarin Corp PLC’s latest SEC Form 4 shows a senior officer’s share hike and RSU grant, underscoring leadership confidence in its cardiovascular drug pipeline and long‑term strategy.

Amarin Corp. exec ups stake to 6,000+ shares, shifts ADS ratio, and exercises RSUs—insight into biotech equity moves that could influence investor views.

Amarin Corporation PLC’s surge on the Frankfurt Stock Exchange underscores its growing promise in cardiovascular therapeutics, driven by a robust pipeline, key partnerships, and strong investor confidence.

Amarin Corporation PLC’s upcoming Q4/2025 results reveal a recovering but volatile stock, spotlighting its cardiovascular drug pipeline and investor hopes.